Preclinical evaluation of an antibody-based companion diagnostic for CD44v6 expressing cancer
FcRn-binding mutations in full-size antibodies significantly alter their in-vivo pharmacokinetics without affecting binding affinity or specificity. Introducing these mutations enables earlier imaging time points, enhancing the potential for companion diagnostics in clinical settings.
Authors
- Leif Dahllund
- Maryam Oroujeni (ORCID: https://orcid.org/0000-0003-2660-9837)
- Fredrik Y. Frejd (ORCID: https://orcid.org/0000-0002-6421-4142)
- Ram Kumar Selvaraju (ORCID: https://orcid.org/0000-0001-9219-1497)
- Helena Persson
- Anja C.L. Mortensen
Institutions
- Uppsala University (SE)
- Karolinska Institutet (SE)
- Discovery Laboratories (United States) (US)
- Pediatrics and Genetics (US)
Publication Details
- Journal
- Nuclear Medicine Communications
- Published
- 2026-01-06
- DOI
- https://doi.org/10.1097/mnm.0000000000002100
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00